Brainstorm Cell Therapeutics Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDBrainstorm Cell Therapeutics Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 88), indicating clear outperformance against the broad market. Earnings growth of 58% provides fundamental context to the price action. However, price is extended 22% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.83 | +11.67% | ABOVE |
| 50 SMA | $0.77 | +21.52% | ABOVE |
| 100 SMA | $0.76 | +23.06% | ABOVE |
| 150 SMA | $0.70 | +32.44% | ABOVE |
| 200 SMA | $0.70 | +33.30% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BCLI in an uptrend right now?
BCLI has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, BCLI is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is BCLI overbought or oversold?
BCLI's RSI (14) is 68. The stock is in neutral territory, neither overbought nor oversold.
Is BCLI outperforming the market?
BCLI has a Relative Strength (RS) Rating of 88 out of 99. Yes, BCLI is a market leader, outperforming 88% of all stocks over the past 12 months.
Where is BCLI in its 52-week range?
BCLI is trading at $0.93, which is 70% of its 52-week high ($1.32) and 55% above its 52-week low ($0.46).
How volatile is BCLI?
BCLI has a Beta of 0.88 and 52-week volatility of 86%. It's less volatile than the S&P 500 - generally more stable.